Hao Haifeng, Wang Xinyu, Qin Yan, Ma Zhifang, Yan Pengyu, Liu Chao, Chen Guanying, Yang Xiaofeng
Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China.
School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, China.
Front Oncol. 2023 Mar 1;13:1083553. doi: 10.3389/fonc.2023.1083553. eCollection 2023.
The low detection rate of early-stage and small tumors remains a clinical challenge. A solution to this unmet need is urgently warranted for the accurate diagnosis and treatment of bladder cancer (BC). This study aimed to evaluate the feasibility of CD47 as a target for optical molecular imaging of human BC and conduct preliminary imaging experiments.
Using indocyanine green (ICG) and a CD47 antibody (anti-CD47), we synthesized a new targeted fluorescent probe ICG-anti-CD47. A total of 25 patients undergoing radical cystectomy were prospectively included in imaging experiments. Following surgery, the freshly isolated bladder specimens were incubated with ICG-anti-CD47, and images were captured under white light and near-infrared (NIR) light. Standard histopathologic evaluation was performed, and findings were correlated with those of CD47-targeted NIR molecular imaging.
Based on the imaging experiments, 23 and 2 patients were pathologically diagnosed with bladder urothelial carcinoma and bladder squamous cell carcinoma, respectively. There were no adverse effects of ICG-anti-CD47 on the histological structure of the tumor and normal uroepithelium. In the NIR grayscale images, the mean fluorescence intensity of the tumor tissue was significantly higher than that of the adjacent normal background tissue, which markedly improved tumor visualization.
Anti-CD47-targeted NIR molecular imaging may be a feasible and powerful strategy for the accurate diagnosis of BC. Nevertheless, larger-scale randomized trials are warranted to verify the present findings.
早期和小肿瘤的低检出率仍然是一项临床挑战。迫切需要找到解决这一未满足需求的方法，以实现膀胱癌（BC）的准确诊断和治疗。本研究旨在评估CD47作为人膀胱癌光学分子成像靶点的可行性，并进行初步成像实验。
我们使用吲哚菁绿（ICG）和一种CD47抗体（抗CD47）合成了一种新型靶向荧光探针ICG-抗CD47。共有25例行根治性膀胱切除术的患者被前瞻性纳入成像实验。手术后，将新鲜分离的膀胱标本与ICG-抗CD47孵育，并在白光和近红外（NIR）光下采集图像。进行标准组织病理学评估，并将结果与CD47靶向的近红外分子成像结果相关联。
基于成像实验，23例和2例患者分别被病理诊断为膀胱尿路上皮癌和膀胱鳞状细胞癌。ICG-抗CD47对肿瘤和正常尿路上皮的组织结构没有不良影响。在近红外灰度图像中，肿瘤组织的平均荧光强度明显高于相邻的正常背景组织，显著改善了肿瘤的可视化效果。
抗CD47靶向的近红外分子成像可能是一种用于膀胱癌准确诊断的可行且有力的策略。然而，需要进行更大规模的随机试验来验证目前的研究结果。
